Atai Beckley Inc.

AtaiBeckley Inc. (NASDAQ: ATAI) is a clinical-stage biopharmaceutical company formed in November 2025 through the strategic combination of atai Life Sciences N.V. and Beckley Psytech Limited, dedicated to transforming patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. Headquartered in New York, NY, the company operates across the United States, Germany, and Canada, with a robust pipeline of psychedelic and non-psychedelic compounds targeting treatment-resistant depression (TRD), social anxiety disorder, schizophrenia-related cognitive impairment, and other psychiatric conditions. Its lead assets include BPL-003 (intranasal mebufotenin benzoate) in Phase 3 planning for TRD, VLS-01 (DMT buccal film) and EMP-01 (oral R-MDMA) in Phase 2 clinical development, as well as a drug discovery program targeting novel non-hallucinogenic 5-HT2A receptor agonists for opioid use disorder and TRD. Formerly known as Atai Beckley N.V., the company completed its redomiciliation to the United States as a Delaware-incorporated entity in December 2025, with its shares continuing to trade on the NASDAQ Global Market under the ticker symbol ATAI.